CX-516

CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and had been undergoing development by a collaboration between Cortex, Shire, and Servier. It was studied as a potential treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD.

CX-516
Pharmacokinetic data
Elimination half-life45 minutes
Identifiers
IUPAC name
  • 6-(Piperidin-1-ylcarbonyl)quinoxaline
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.237.047
Chemical and physical data
FormulaC14H15N3O
Molar mass241.294 g·mol−1
3D model (JSmol)
SMILES
  • O=C(c2cc1nccnc1cc2)N3CCCCC3
InChI
  • InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2 Y
  • Key:ANDGGVOPIJEHOF-UHFFFAOYSA-N Y
  (verify)

CX-516 was the first ampakine compound developed by Cortex and while it showed good in vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However, CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as farampator and CX-717 are compared to.

See also

References
  • Danysz W (July 2002). "CX-516 Cortex pharmaceuticals". Current Opinion in Investigational Drugs. 3 (7): 1081–8. PMID 12186271.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.